Senior GSK exec Richard Saynor revealed as new Sandoz CEO
pharmafile | April 25, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Novartis, Sandoz, appointment, pharma
Novartis has seen a major leadership change within its business, as the company announced that senior GlaxoSmithKline exec Richard Saynor would be stepping up to lead Sandoz, its biosimilars and generics division, as CEO from no later than 1 August.
He will step into the position which was originally vacated by ex-CEO Richard Francis at the end of March. The role has been filled on an interim basis since then.
Saynor, who is currently serving as Senior Vice President, Classic and Established Products, Commercial & Digital Platforms at GSK, has spent more than 20 years of leadership experience across branded and generic products. In his current role, he oversees GSK’s Established Products portfolio which is valued at $10 billion and encompasses more than 350 brands in over 120 countries.
Novartis celebrated Saynor for “a successful track record, building strong interfaces between commercial and technical operations as well as driving commercial excellence across his organisation.”
The move is something of a homecoming for Saynor, who worked at Sandoz prior to his stint at GSK in positions leading commercial operations, where he helped manage an expansion of Sandoz’ generics business across Asia, Latin America and Turkey.
Novartis has announced that the US Food and Drug Administration has approved Fabhalta (iptacopan) as …
Sandoz has announced that it has entered into a development and commercialisation agreement with Samsung …